- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03276156
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Studieoversigt
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Zhejiang Cancer Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Fully informed consent prior to any specific research procedure.
- Adult patients, aged ≥18 years;
Imaging test confirmed the progression after first-line treatment of advanced gastric adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.
- S-1 was not used in the first-line treatment
- If patient relapse in 6 months after adjuvant chemotherapy or neoadjuvant chemotherapy, the adjuvant chemotherapy or neoadjuvant chemotherapy was regarded as the first-line treatment.
- Adjuvant chemotherapy or neoadjuvant chemotherapy was allowed if the first-line treatment started beyond 6 months after the end of previous treatment.
- During the research ,patient should be willing and be able to follow the process treatment ,follow up and tests.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
- Survival expectation ≥ 16 weeks from the planned first dosing .
- During the 28 days prior to the first dosing, hematological, biochemical and Organ Functions:HB ≥ 9.0 g/dL, ANC ≥ 1.5×109/L,WBC>3×109/L, PLT ≥ 100×109/L, BIL < 1.5×ULN, ALT or AST < 2.5×ULN (or < 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN;
Lesions ,measurable and/or unmeasurable,at least one,can be assessed by imaging during the baseline and follow-up measurement.
- Localized mass in gastric or Gastroesophageal Junction belongs to unmeasurable Lesions.
Women, those postmenopausal or of child-bearing age, but the pregnancy test results (serum or urine) within 28 days before treatment is negative, and the results should be confirmed in day 1 of the treatment.
- Postmenopausal women are defined as :woman's menstrual periods have ceased for 1 year or longer after exogenous hormone therapy;
- Women, aged>50years,serum LH and FSH level show a postmenopause;
- Woman has radiation induced ovarian failure,and gone without a period for over 12 consecutive months;
- Woman has chemotherapy-induced menopause and gone without a period for over 12 consecutive months;
- sterilization operation( hysterectomy or bilateral oophorectomy)
Exclusion Criteria:
- Has participated in another clinical trial in progress.
- Has received more than one chemotherapy regimens after disease progression(except for those who has receiced adjuvant chemotherapy or neoadjuvant chemotherapy 6 months or longer)
- Previous therapy with S-1
- Has received VEGFR inhibitor, such as Sorafenib,Sunitinib .
- Has another primary tumor,but adequately treated non-melanoma skin cancer , effectively treated carcinoma in situ of cervix and other well handled cancer over 5 years were not covered.
- Has difficulty in swallowing
- Has taken experimental drugs within 14 days before randomly assign.( For different drug characteristics, the interval can be longer)
- History of any chemotherapy, radiotherapy,the last administration should finish within 3 weeks prior to trial first drug administration( For different drug characteristics, the interval can be longer). If steady dose of diphosphate or denosumab is necessary for the treatment of bone metastases,the administration should start 3-4weeks prior to the study .
- Patients with poor-controlled arterial hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I, arrhythmia greater than Class I (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), and cardiac dysfunction greater than Class I;
- Has persistent toxicity (exclude alopecia )of previous treatment ,CTCAE>1.
- Has intestinal obstruction or upper gastrointestinal hemorrhage(CTCAE 3 or 4) within 4 weeks prior to randomly assign.
- Abnormal coagulation function (INR > 1.5×ULN, APTT > 1.5×ULN), with tendency of bleed;
- Has symptom of brain metastases and the tendency out of control,but imaging confirmed is not required.If steady dose of Glucocorticoid is necessary for the treatment,the administration should be started >4weeks prior to the study . Patients with spinal cord compression received definite treatment and the situation had been proven stable in 28days .
- Has surgery within 2 weeks prior to the study. Eligible patients should recovered from any major surgery.
- Subjects that are unable to swallow tablets, chronic diarrhea ,or intestinal obstruction;
- Subjects with a clear tendency of gastrointestinal bleeding;
- Pregnant or lactating women;
- Other conditions regimented at investigators' discretion.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Apatinib plus S-1
Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
|
Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Progression Free Survival(PFS)
Tidsramme: Event driven, an expected average of 4 months
|
Event driven, an expected average of 4 months
|
Incidence of adverse events
Tidsramme: An expected average of 4 months
|
An expected average of 4 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall survival(OS)
Tidsramme: An expected average of 12months
|
An expected average of 12months
|
Disease control rate(DCR)
Tidsramme: An expected average of 4 months
|
An expected average of 4 months
|
Objective response rate(ORR)
Tidsramme: An expected average of 4 months
|
An expected average of 4 months
|
Quality of life(QoL)
Tidsramme: An expected average of 12 months
|
An expected average of 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Neoplasmer i maven
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Proteinkinasehæmmere
- Apatinib
Andre undersøgelses-id-numre
- Ahead-G001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mavekræft
-
Medtronic - MITGAfsluttet
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertikal ærmegatrektomi | Mavebånd | Bypass, GastricForenede Stater
-
DuomedAktiv, ikke rekrutterendeFedme | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgien
-
Olympus Corporation of the AmericasUnity Health TorontoAfsluttet
-
North Dakota State UniversityNational Institutes of Health (NIH)AfsluttetRoux en Y Gastric Bypass OperationForenede Stater
-
Rijnstate HospitalAfsluttetRoux-en-Y Gastric Bypass | Mavetømning | Bariatrisk kirurgiHolland
-
Wageningen UniversityRijnstate HospitalUkendtRoux-en-Y Gastric BypassHolland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAfsluttetRoux en Y Gastric BypassForenede Stater
-
Rijnstate HospitalAfsluttet
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAfsluttetSleeve Gastrectomy | Roux en Y Gastric BypassForenede Stater
Kliniske forsøg med Apatinib plus S-1
-
Changzhou Cancer Hospital of Soochow UniversityAfsluttetIkke-småcellet lungekræftKina
-
Hebei Medical University Fourth HospitalUkendtRefraktær eller metastatisk esophageal planocellulær karcinomKina
-
Tianjin Medical University Cancer Institute and...Ukendt
-
Peking University Cancer Hospital & InstituteRekruttering
-
Taiho Pharmaceutical Co., Ltd.Afsluttet
-
Henan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.UkendtKolorektal cancerKina
-
Kyungpook National University HospitalUkendtMavekræftKorea, Republikken
-
Ruijin HospitalAktiv, ikke rekrutterendeGastrisk og Gastroøsofageal Junction (GEJ) AdenocarcinomKina
-
Xijing HospitalUkendt
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong...Aktiv, ikke rekrutterendeKolorektal cancer | Mikrosatellit-ustabilitet højKina